Taysha Gene Therapies, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • September 18th, 2020 • Taysha Gene Therapies, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledSeptember 18th, 2020 Company Industry JurisdictionTaysha Gene Therapies, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”), for whom you are acting as the representatives (the “Representatives”), an aggregate of [•] shares (the “Firm Shares”) and, at the election of the Underwriters, up to [•] additional shares (the “Optional Shares”) of common stock, par value $[•] per share (“Stock”), of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).